{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T08:43:23Z","timestamp":1768725803947,"version":"3.49.0"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,8,26]],"date-time":"2005-08-26T00:00:00Z","timestamp":1125014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Tioguanine (thioguanine) has been proposed as a rescue thiopurine for azathioprine or mercaptopurine intolerant inflammatory bowel disease patients. The use of tioguanine leads to high 6\u2010tioguaninenucleotide (6\u2010thioguaninenucleotide) levels in red blood cells but, contra\u2010intuitively, these have yet not been associated with an increased risk of myelotoxicity.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To assess the role of 6\u2010tioguaninenucleotide concentrations in developing myelotoxicity during tioguanine treatment.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002Database analysis of 25 patients treated with tioguanine. Clinical findings and laboratory parameters were related to 6\u2010tioguaninenucleotide levels.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002One patient developed a myelodepression (21\u2003mg TG\/day for 3\u2003months and 6\u2010tioguaninenucleotide 714\u2003pmol\/8\u2003\u00d7\u200310<jats:sup>8<\/jats:sup> red blood cells). 6\u2010Tioguaninenucleotide levels varied greatly between individuals (mean 6\u2010tioguaninenucleotide level 621\u2003pmol\/8\u2003\u00d7\u200310<jats:sup>8<\/jats:sup> red blood cells, s.d. 340\u2003pmol\/8\u2003\u00d7\u200310<jats:sup>8<\/jats:sup> red blood cells and range 34\u20131653\u2003pmol\/8\u2003\u00d7\u200310<jats:sup>8<\/jats:sup> red blood cells). The TG dosages (mean 20.6\u2003mg\/day and median 20\u2003mg\/day) did not correlate with 6\u2010tioguaninenucleotide levels (<jats:italic>r<\/jats:italic>\u2003=\u20030.31, N.S.). High 6\u2010tioguaninenucleotide levels (&gt;450\u2003pmol\/8\u2003\u00d7\u200310<jats:sup>8<\/jats:sup> red blood cells) did not effect haemoglobin concentrations (mean 8\u2003mmol\/L), peripheral leucocyte (mean 7.5\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/L) or platelet counts (mean 298\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/L). No correlations were established between laboratory parameters, type of disease and 6\u2010tioguaninenucleotide level.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> :\u2002High 6\u2010tioguaninenucleotide levels in erythrocytes (&gt;450\u2003pmol\/8\u2003\u00d7\u200310<jats:sup>8<\/jats:sup>) during TG treatment compared to azathioprine or mercaptopurine treatment are not indicative for (developing) myelotoxicity.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02581.x","type":"journal-article","created":{"date-parts":[[2005,8,26]],"date-time":"2005-08-26T09:11:04Z","timestamp":1125047464000},"page":"447-451","source":"Crossref","is-referenced-by-count":23,"title":["On the limitation of 6\u2010tioguaninenucleotide monitoring during tioguanine treatment"],"prefix":"10.1111","volume":"22","author":[{"given":"N. K. H.","family":"DE BOER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"DE GRAAF","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"WILHELM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J. J.","family":"MULDER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"VAN BODEGRAVEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,26]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2004.09.029"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/00855920310002726"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.6.874a"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200108000-00001"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200504000-00012"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00938-7"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.8.1081"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70140-5"},{"key":"e_1_2_5_10_2","first-page":"1298","article-title":"Azathioprine myelotoxicity related to elevated 6\u2010thioguanine nucleotides in heart transplantation","volume":"27","author":"Schutz E","year":"1995","journal-title":"Transplant Proc"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01947.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07413.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200301000-00011"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200406000-00016"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.5.665"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01683.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01590.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0442-6"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16432"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02581.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02581.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:30:46Z","timestamp":1697416246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02581.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,26]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02581.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02581.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,26]]}}}